Supplementary Materials

Supplementary Material for:

High-throughput sequencing of the T cell receptor β gene identifies aggressive early-stage mycosis fungoides

Adele de Masson, John T. O'Malley, Christopher P. Elco, Sarah S. Garcia, Sherrie J. Divito, Elizabeth L. Lowry, Marianne Tawa, David C. Fisher, Phillip M. Devlin, Jessica E. Teague, Nicole R. Leboeuf, Ilan R. Kirsch, Harlan Robins, Rachael A. Clark,* Thomas S. Kupper*

*Corresponding author. Email: tkupper{at}bwh.harvard.edu (T.S.K.); rclark{at}bwh.harvard.edu (R.A.C.)

Published 9 May 2018, Sci. Transl. Med. 10, eaar5894 (2018)
DOI: 10.1126/scitranslmed.aar5894

This PDF file includes:

  • Fig. S1. Clinical pictures of two patients with stage IB MF.
  • Fig. S2. TCR Vβ high-throughput sequencing allows specific quantification of the frequency of the malignant T cell clone within a Vβ gene family.
  • Fig. S3. Continuous relationship between the TCF and the HRs for PFS and OS.
  • Fig. S4. Prognostic value of the CLIPI in early-stage MF.
  • Fig. S5. TCF in patches versus plaques.
  • Fig. S6. Prognosis in early-stage patients according to body surface area involved and the presence of plaques.
  • Fig. S7. Prognosis in stage IA patients.
  • Fig. S8. Reproducibility of the TCF as measured by high-throughput sequencing of the TCRβ gene in different lesions in the same patient.
  • Fig. S9. PFS and OS in pretreated and treatment-naïve early-stage MF patients.
  • Table S1. ISCL/EORTC classification and staging of MF and SS.
  • Table S2. Clinical characteristics of 208 patients with CTCL in the discovery set.
  • Table S3. Clinical characteristics of 101 patients with CTCL in the validation set.
  • Table S4. Multivariable analysis on PFS in early-stage patients.

[Download PDF]